The global Rapid Medical Diagnostic Kits market, valued at $28.11 billion in 2025, is projected to grow to $67 billion by 2035 at a CAGR of 9.06%. Growth is fueled by increasing infectious and chronic diseases, technological innovations like AI and biosensors, and rising consumer demand for home testing. North America leads with 37% market share, while Asia Pacific is the fastest-growing region. The market benefits from government support, expanding point-of-care diagnostics, and digital health integration, with key players including Abbott and Roche driving innovation.
Abbott received FDA De Novo authorization for Libre Duo 10 Day, the first wearable device that continuously monitors glucose and detects rising ketone levels, which can signal diabetic ketoacidosis. This regulatory milestone sets Abbott apart in diab...
Abbott has received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce stroke risk in patients with atrial fibrillation (AFib) by sealing the heart's left atrial appendage (LAA). The device...
Abbott has received FDA authorization for its Libre Duo 10 Day system, the world's first biowearable device that continuously monitors both glucose and ketone levels. This innovation helps people with diabetes detect rising ketones early, which can p...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
